Document Type

Article

Publication Date

1-24-2025

Comments

This article is the author’s final published version in ACR Open Rheumatology, Volume 7, Issue 1, Jan 2025, Article number e11787.

The published version is available at https://doi.org/10.1002/acr2.11787. Copyright © 2025 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Publication made possible in part by support through a transformative agreement between Thomas Jefferson University and the publisher.

Abstract

OBJECTIVE: Evaluate prevalence of new onset autoimmune conditions (ACs) after commencement of immune checkpoint inhibitors (ICIs).

METHODS: This retrospective observational study was done using TriNetX. Patients with neoplasm for which ICIs were approved were stratified into two groups based on ICI use. Multivariate Cox proportional hazard models and Kaplan Meier method were used to assess risk of developing ACs among the groups. Subgroup analysis was done to evaluate risk of ACs in patients receiving cytotoxic T-lymphocyte-associated protein 4 inhibitor (CTLA4i) versus program cell death protein 1 inhibitor (PD1i) and program death ligand 1 inhibitor (PDL1i) inhibitors and combination treatment (CT) (CTLA4 + PD1i/PDL1i) versus PD1i/PDL1i.

RESULTS: Patients who received ICIs (2.03% of total population) were younger (68.7 ± 12.6 vs 71.8 ± 13.9; P < 0.001), predominantly male (54% vs 41%; P < 0.0001), and White (68% vs 58%; P < 0.0001), had lower odds of developing systemic lupus erythematosus (SLE) (0.366% vs 0.437%, odds ratio [OR] 0.837; P = 0.0005) and systemic sclerosis (0.108% vs 0.135%, OR 0.796; P = 0.0151), and had higher odds of developing rheumatoid arthritis (RA) (2.194% vs 1.752%, OR 1.258; P < 0.0001 with hazard ratio 1.746; P < 0.0001). There was no significant difference in developing vasculitis, dermatopolymyositis, and psoriatic arthritis when compared to patients who did not receive ICIs. The prevalence of ACs remained true after propensity score matching, except that there was no difference compared with the prevalence of SLE (0.37% [n = 391] vs 0.393% n = 415], OR 0.942 [0.82-1.082]; P = 0.3970).

CONCLUSION: Patients receiving ICIs have an increased risk of developing ACs, especially RA. There needs to be a high index of suspicion and awareness about ACs for prescribers of ICIs.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Additional Files
acr211787-sup-0001-disclosureform.pdf (525 kB)

Language

English

Download

Share

COinS